Shares of Lupin Ltd were trading in the red and 1% lower on 3 August despite the company announcing that it has secured a US Food and Drug Administration (USFDA) approval for its Diazepam Injection USP, 10 mg/2 mL (5 mg/mL) in single-dose prefilled syringes.

The approval opens the door for Lupin to enter a $77.9 million US market, strengthening its portfolio of complex injectable medicines.

The approved product is a generic version of Valium Injection and is indicated for the management of anxiety disorders and the short-term relief of anxiety symptoms. It has been approved through Lupin’s Abbreviated New Drug Application (ANDA) and has been found to be bioequivalent to the reference product marketed in the US.

This approval is another step in Lupin’s strategy of expanding its presence in the US generics market through complex and value-added products. Prefilled injectable medicines typically face higher entry barriers than conventional tablets, which can help companies improve profitability and reduce pricing pressure from competition.

The latest regulatory clearance follows several recent approvals secured by Lupin in key global markets, reflecting the company’s continued focus on strengthening its product pipeline. The US remains one of Lupin’s most important markets, and new product launches are expected to support future revenue growth.

With an estimated annual market opportunity of $77.9 million, the approval adds another growth avenue for the company while reinforcing its position in the specialised injectables segment.

At 12:10 pm, the shares of Lupin were trading 1.45% lower at Rs 2,379.90 on the NSE.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!